NO996161L - A controlled release formulation for heavily soluble basic drugs - Google Patents
A controlled release formulation for heavily soluble basic drugsInfo
- Publication number
- NO996161L NO996161L NO996161A NO996161A NO996161L NO 996161 L NO996161 L NO 996161L NO 996161 A NO996161 A NO 996161A NO 996161 A NO996161 A NO 996161A NO 996161 L NO996161 L NO 996161L
- Authority
- NO
- Norway
- Prior art keywords
- controlled release
- release formulation
- soluble basic
- basic drugs
- heavily soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO996161A NO310095B1 (en) | 1997-06-11 | 1999-12-13 | A controlled release formulation for heavily soluble basic drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/010705 WO1998056357A1 (en) | 1995-12-19 | 1997-06-11 | A controlled release formulation for poorly soluble basic drugs |
NO996161A NO310095B1 (en) | 1997-06-11 | 1999-12-13 | A controlled release formulation for heavily soluble basic drugs |
Publications (3)
Publication Number | Publication Date |
---|---|
NO996161D0 NO996161D0 (en) | 1999-12-13 |
NO996161L true NO996161L (en) | 1999-12-13 |
NO310095B1 NO310095B1 (en) | 2001-05-21 |
Family
ID=22261117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO996161A NO310095B1 (en) | 1997-06-11 | 1999-12-13 | A controlled release formulation for heavily soluble basic drugs |
Country Status (4)
Country | Link |
---|---|
NO (1) | NO310095B1 (en) |
SI (1) | SI20108B (en) |
SK (1) | SK282427B6 (en) |
WO (1) | WO1998056357A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3668000A (en) * | 1999-04-29 | 2000-11-17 | Russinsky Limited | Compounds |
EP1118333A1 (en) * | 2000-01-18 | 2001-07-25 | Eurand International S.P.A. | Compositions with enhanced oral bioavailability |
CN100341886C (en) * | 2000-11-27 | 2007-10-10 | 桑多斯股份公司 | Macrolide solvates |
KR20050014802A (en) * | 2002-04-03 | 2005-02-07 | 랜박시 래보러터리스 리미티드 | Taste masked compositions of erythromycin a and derivatives thereof |
SI21300A (en) * | 2002-10-08 | 2004-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical compositions with alginates |
CN100336511C (en) * | 2002-11-15 | 2007-09-12 | 江苏豪森药业股份有限公司 | Release-controlled oral Roxithromycin formulation |
CA2673334C (en) * | 2003-06-16 | 2013-11-12 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
EP3544614A4 (en) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60163823A (en) * | 1984-02-03 | 1985-08-26 | Taisho Pharmaceut Co Ltd | Oral administration pharmaceutical |
ATE66143T1 (en) * | 1985-01-11 | 1991-08-15 | Abbott Lab | SLOW RELEASE SOLID PREPARATION. |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
-
1997
- 1997-06-11 SK SK1612-99A patent/SK282427B6/en not_active IP Right Cessation
- 1997-06-11 WO PCT/US1997/010705 patent/WO1998056357A1/en active Application Filing
- 1997-06-11 SI SI9720096A patent/SI20108B/en unknown
-
1999
- 1999-12-13 NO NO996161A patent/NO310095B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO310095B1 (en) | 2001-05-21 |
NO996161D0 (en) | 1999-12-13 |
WO1998056357A1 (en) | 1998-12-17 |
SK161299A3 (en) | 2000-05-16 |
SI20108B (en) | 2001-12-31 |
SK282427B6 (en) | 2002-01-07 |
SI20108A (en) | 2000-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL121275A0 (en) | A controlled release formulation for poorly soluble basic drugs | |
MA26576A1 (en) | EXTENDED RELEASE ORAL PHARMACEUTICAL FORMULATION | |
MA26577A1 (en) | PULSED RELEASE ORAL PHARMACEUTICAL FORMULATION | |
NO20000735L (en) | Sustained release drug delivery device | |
ATE234078T1 (en) | PHARMACEUTICAL OMEPRAZOLE FORMULATION | |
EE200000098A (en) | A pharmaceutical composition for combining piperidinoalkanol decongestant | |
EP1124543A4 (en) | Controlled release formulation for water soluble drugs | |
FIU20000164U0 (en) | A new pharmaceutical formulation | |
EE200000361A (en) | Device for administering a drug-containing fluid | |
DE69904312D1 (en) | PHARMACEUTICAL AEROSOL FORMULATION | |
BR9607752B1 (en) | controlled release microcapsule pharmaceutical formulation. | |
ZA982872B (en) | Pharmaceutical formulation | |
NO996161D0 (en) | A controlled release formulation for heavily soluble basic drugs | |
NO20002126L (en) | Extended release formulation | |
NO20001375D0 (en) | Drug formulation with controlled release | |
HK1045465A1 (en) | A pharmaceutical formulation comprising megalatranand its prodrug | |
PT868911E (en) | RAPAMICINE FORMULATIONS FOR ORAL ADMINISTRATION | |
EE9900545A (en) | A pharmaceutical composition | |
AU5026599A (en) | A wet granulation method for preparing a stable pharmaceutical formulation | |
NO996044L (en) | Rapamycin formulations for oral administration | |
GB9709739D0 (en) | Pharmaceutical formulation | |
NO980072D0 (en) | Soluble release mechanism for moving joints | |
HRP970325B1 (en) | Controlled release formulation for poorly soluble basic drugs | |
GB9724175D0 (en) | A pharmaceutical formulation | |
ZA99349B (en) | A pharmaceutical formulation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BGP PRODUCTS OPERATIONS GMBH, CH |
|
MK1K | Patent expired |